MedImmune's Second Shot at the Flu

Its FluMist nasal-spray vaccine now has a chance to shine. Too bad the biotech lacks the production capacity to fully exploit the opening

By Sarah Lacy

To continue reading this article you must be a Bloomberg Professional Service Subscriber.